|
|
Post by jeremg on Dec 4, 2015 19:40:34 GMT -5
What about this for some play suppose, 1.- Mannkind was in talks with Sanofi from way back, before the second CRL was given by the FDA. 2.- After the CRL, Sanofi wanted to see an approval before a commitment. 3.- Mannkind got the approval and Sanofi signed the deal 4.- Unfortunately for us, Sanofi got rid of the visionary CEO, Viehbacher, that saw real potential on Afrezza and Technosphere. 5.- Brandicourt decides to play it safe from day one, especially having seen what happen to his predecessor. 6.- Mannkind is assured that the deal is still good, but slowly realizes of reality. 7.- Brandicourt focuses on Toujeo, theoretically a much safer bet, even if in retrospect it was the wrong thing to do. 8.- Brandicourt has set us back anywhere between 12 to 18 months in the introductions of Afrezza, if not more. 9.- Mannkind finally catches up with reality and is struggling to figure out how to move forward. First steep get rid of CEO that was never supposed to face the current situation. 10.- Now we really need to start working about what other new technologies might come along that might present a challenge to TS. i.e. www.oramed.com/oramed-signs-up-to-50-million-licensing-and-investment-agreements-for-oral-insulin-capsule-in-china/
None of this makes me happy, but it rings true a lot more than all the fanfare and speculation of Mr. Mann having everybody where he always wanted them before he unleashes hell to his enemies. There is no reason for us to even think about this while we're figuring out how to keep the lights on for another few months. I think your progression of events is likely and I cannot stress what an enormous change in fortune I think the firing and hiring of Brandicourt was for us. The question is where do we go from here [after the financing is settled which is first and foremost]. I think Al needs to do some SNY soul searching and assess their intent SOON. |
|
|
|
Post by gamblerjag on Dec 4, 2015 19:51:02 GMT -5
the most we are currently set back is 6-7 months.. but in reality I would say 5-6 months.. since the scripts are currently where many of us were expecting/hoped after 2-3 months.
|
|
|
|
Post by mssciguy on Dec 4, 2015 19:54:38 GMT -5
jeremg also, Does mnkd want to be a product development company, or an Afrezza production company. The wisest move might be to separate the two so that everyone knows their jobs. Human insulin by Technospere was quite a triumph. The smaller molecules or peptides should be a cake walk, so why haven't we seen any?
|
|
|
|
Post by bill on Dec 4, 2015 19:56:04 GMT -5
Ugh, here I go again with the downer post haha. Oh well... someone has to I guess. I'll be that guy for now. It's just as likely, if not more so, that the reason it's been so quiet is because nothing is happening...Horses and Zebras, glad to see someone else isn't hallucinating Zebras. That's really not a fair comment. If you want to say "nothing is happening" then are we to assume that your position is that you believe SNY is done with Afrezza? And, therefore your position is that SNY won't be spending a dime more than necessary between now and January when they'll terminate the partnership? Or something else. |
|
|
|
Post by ricguy on Dec 4, 2015 20:01:39 GMT -5
There may not be many here who believe me, and I guess I don't blame them, but I'm not here to try to quell any optimism. In the last week we've gotten word of a top secret meeting in San Diego that may or may not be happening and people went from being doom and gloom to pie in the sky. We need to try to stay a little more even keel and stay rooted in facts. My optimism came much before this so called "meeting" and this "meeting" hasn't swayed me one way or another until/if I ever know what it is about. I agree with your sentiment, I'm not putting much faith in the "meeting" as of yet and we still have a long way to go. I started feeling some optimism when they dumped Hakan and that impacted my decision to buy more. It showed me they aren't going to sit on their ass. Yes the argument could be made that he left on his own because he didn't like what is coming and that would be even worse but no one here really knows what the heck is going on (some good educated guesses) so until I get some concrete facts I'm relying on my instincts. |
|
|
|
Post by bill on Dec 4, 2015 20:01:24 GMT -5
What about this for some play suppose, 1.- Mannkind was in talks with Sanofi from way back, before the second CRL was given by the FDA. 2.- After the CRL, Sanofi wanted to see an approval before a commitment. 3.- Mannkind got the approval and Sanofi signed the deal 4.- Unfortunately for us, Sanofi got rid of the visionary CEO, Viehbacher, that saw real potential on Afrezza and Technosphere. 5.- Brandicourt decides to play it safe from day one, especially having seen what happen to his predecessor. 6.- Mannkind is assured that the deal is still good, but slowly realizes of reality. 7.- Brandicourt focuses on Toujeo, theoretically a much safer bet, even if in retrospect it was the wrong thing to do. 8.- Brandicourt has set us back anywhere between 12 to 18 months in the introductions of Afrezza, if not more. 9.- Mannkind finally catches up with reality and is struggling to figure out how to move forward. First steep get rid of CEO that was never supposed to face the current situation. 10.- Now we really need to start working about what other new technologies might come along that might present a challenge to TS. i.e. www.oramed.com/oramed-signs-up-to-50-million-licensing-and-investment-agreements-for-oral-insulin-capsule-in-china/
None of this makes me happy, but it rings true a lot more than all the fanfare and speculation of Mr. Mann having everybody where he always wanted them before he unleashes hell to his enemies. . I think your progression of events is likely and I cannot stress what an enormous change in fortune I think the firing and hiring of Brandicourt was for us. The question is where do we go from here [after the financing is settled which is first and foremost]. I think Al needs to do some SNY soul searching and assess their intent SOON. - Why are you throwing out FUD in the highlighted text? There have been multiple posts that have objectively shown that MNKD has at least 4 quarters of cash available to them as of this beginning of this quarter, i.e., near-term bankruptcy is not relevant. |
|
|
|
Post by jeremg on Dec 4, 2015 20:02:13 GMT -5
jeremg also, Does mnkd want to be a product development company, or an Afrezza production company. The wisest move might be to separate the two so that everyone knows their jobs. Human insulin by Technospere was quite a triumph. The smaller molecules or peptides should be a cake walk, so why haven't we seen any? I agree 100% but it is still unknown to us whether this would even be a possibility for Al to explore given MNKD's exceedingly weak positioning. Back when I was a ray of sunshine with regards to this investment, I had dreams that MNKD would sell of Afrezza, I would make back my principal investment (or more) and then hold [Mannkind Technologies] for many years to come before cashing in on the "embarrassment of riches", seems a ridiculous thought now... |
|
|
|
Post by mssciguy on Dec 4, 2015 20:02:52 GMT -5
Horses and Zebras, glad to see someone else isn't hallucinating Zebras. That's really not a fair comment. If you want to say "nothing is happening" then are we to assume that your position is that you believe SNY is done with Afrezza? And, therefore your position is that SNY won't be spending a dime more than necessary between now and January when they'll terminate the partnership? Or something else. Agree bill .. mnkd is down to about 300 employees now, a lot of folks were let go. The ones remaining are busy, including Hakan. No doubt about it. Personally I would be happier with a larger staff and more aggressive timelines. Sadly the attacks by GSCO and their hedge fund minions (not to mention the unscrupulous misanthropic and "cutely brilliant" Shrekeli) have deprived the company of funds via indirect but deadly and profitable means. |
|
|
|
Post by jeremg on Dec 4, 2015 20:05:11 GMT -5
Horses and Zebras, glad to see someone else isn't hallucinating Zebras. That's really not a fair comment. If you want to say "nothing is happening" then are we to assume that your position is that you believe SNY is done with Afrezza? And, therefore your position is that SNY won't be spending a dime more than necessary between now and January when they'll terminate the partnership? Or something else. I would be thrilled to know SNY is terminating the partnership, my worst fear is that SNY keeps us locked up at the starting line and MNKD is in such a weak position that they can't even afford to end the partnership on their terms. As you may or may not know, the difference between MNKD dissolving the partnership and SNY dissolving it is an enormous financial debt vs. windfall, which would you prefer? |
|
|
|
Post by bill on Dec 4, 2015 20:05:49 GMT -5
jeremg also, Does mnkd want to be a product development company, or an Afrezza production company. The wisest move might be to separate the two so that everyone knows their jobs. Human insulin by Technospere was quite a triumph. The smaller molecules or peptides should be a cake walk, so why haven't we seen any? One reason I can think of to keep the two together is so MNKD can use Afrezza milestone payments and profits to fund TS developments. If they were separated the MNKD TS company would lose its primary source of funding for TS developments. Without funding, there are no TS products. |
|
|
|
Post by jeremg on Dec 4, 2015 20:09:34 GMT -5
There is no reason for us to even think about this while we're figuring out how to keep the lights on for another few months. I think your progression of events is likely and I cannot stress what an enormous change in fortune I think the firing and hiring of Brandicourt was for us. The question is where do we go from here [after the financing is settled which is first and foremost]. I think Al needs to do some SNY soul searching and assess their intent SOON. - Why are you throwing out FUD in the highlighted text? There have been multiple posts that have objectively shown that MNKD has at least 4 quarters of cash available to them as of this beginning of this quarter, i.e., near-term bankruptcy is not relevant. Excuse me? You just highlighted that text in your response, that was not in my original comment. And that is a very misleading statement, we cannot continue to have these BK scares with insolveny looming a couple months away... that would completely destroy what little is left of our PPS. |
|
|
|
Post by EveningOfTheDay on Dec 4, 2015 20:09:38 GMT -5
There is no reason for us to even think about this while we're figuring out how to keep the lights on for another few months. I think your progression of events is likely and I cannot stress what an enormous change in fortune I think the firing and hiring of Brandicourt was for us. The question is where do we go from here [after the financing is settled which is first and foremost]. I think Al needs to do some SNY soul searching and assess their intent SOON. Yes, thank you. Financing is the real question here. Can Mr. Pfeffer, as a CFO and Invertor Relations contact person, let us know what it will take for MNKD to stay open and how they are planning to achieve this. Please no more wishful answers about how Mr. Mann billions will be there to bail us out. I do not presume to know whether Mr. Mann will put more money into Mannkind or not, although I agree with many that he might not have an option if he wants to protect his original investment, but if he does, I am certain it will come with a price tag for longs, the only question is how high. |
|
|
|
Post by jeremg on Dec 4, 2015 20:11:20 GMT -5
bill it seems that you keep responding to things you do not seem to grasp. MNKD would likely still receive milestones (if they wrote this into a sale with SNY) AND they would use the money from the sale of Afrezza to fund Technosphere Development as MNKD Technologies.
|
|
|
|
Post by bill on Dec 4, 2015 20:15:43 GMT -5
jeremg also, Does mnkd want to be a product development company, or an Afrezza production company. The wisest move might be to separate the two so that everyone knows their jobs. Human insulin by Technospere was quite a triumph. The smaller molecules or peptides should be a cake walk, so why haven't we seen any? One reason I can think of to keep the two together is so MNKD can use Afrezza milestone payments and profits to fund TS developments. If they were separated the MNKD TS company would lose its primary source of funding for TS developments. Without funding, there are no TS products. So, under your hypothesis why would SNY establish a relationship with the early adopters and invite them to San Diego's Del Mar at their expense--particularly if they're keeping the event under wraps? If I were SNY, and I were inclined to slow roll the Afrezza launch indefinitely, I'd make a big deal out of any event that I could subsequently use to show I was making reasonable efforts to commercialize Afrezza. SNY's doing just the opposite. |
|
|
|
Post by jeremg on Dec 4, 2015 20:21:14 GMT -5
jeremg One reason I can think of to keep the two together is so MNKD can use Afrezza milestone payments and profits to fund TS developments. If they were separated the MNKD TS company would lose its primary source of funding for TS developments. Without funding, there are no TS products. So, under your hypothesis why would SNY establish a relationship with the early adopters and invite them to San Diego's Del Mar at their expense--particularly if they're keeping the event under wraps? If I were SNY, and I were inclined to slow roll the Afrezza launch indefinitely, I'd make a big deal out of any event that I could subsequently use to show I was making reasonable efforts to commercialize Afrezza. SNY's doing just the opposite. havenotwantnot - That reasoning is both illogical and absurd (especially based on the fact that it's premised on a meeting we know nothing about). Your speculation on top of speculation cannot be used to prove the point you are trying to prove, it just doesn't work. |
|
